The combination of sintilimab and fruquintinib received conditional approval from China’s National Medical Products Administration (NMPA) for the treatment of patients with advanced endometrial cancer ...

Cancer isn’t just one disease, but many — each with its own challenges, characteristics, risks and treatments. As we have worked tirelessly to understand this group of diseases, I’ve witnessed a ...

A new large-scale study co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators provides the strongest ...

The Association of Cancer Care Centers (ACCC), in collaboration with Eli Lilly and Company, is pleased to announce the seven recipients of the "Improving the Precision Oncology Care Pathway" Request ...

Initial results found that among 1060 participants in 30 countries, the pembrolizumab plus CCRT group conferred better PFS at 24 months than the placebo plus CCRT group (68% vs 57%; hazard ratio [HR], ...

Actinium Pharmaceuticals, Inc. (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced a clinical program comprising of trials studying Actimab-A in ...

Can Your Diet Help Prevent Lung Cancer? Scientists Explore the LinkFor cancers of organs like the liver, the long-term impact of our diet has been ...

PD-1 blockade conferred benefit to certain women with surgically resectable endometrial cancer, findings presented at Society ...

Results from the NRG Oncology GOG-0263 Phase III clinical trial testing the addition of cisplatin-based chemotherapy to ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Humanetics’ Novel Radioprotective Agent Being Developed with Funding from Department of Defense as Radiation Medical Countermeasure (MCM)Lifecore ...

Approval based on ADRIATIC Phase III trial results which showed a 27% reduction in the risk of death versus placebo ...